Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-12-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Change in number of shares and votes in Episurf Medical
Share Issue/Capital Change Classification · 1% confidence The document explicitly details changes in the number of shares and votes due to a 'Directed Share Issue' and the exercise of warrants. It reports the resulting total number of shares, total votes, and the increase in share capital. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2020-12-30 English
Episurf Medical tecknar licensavtal om SEK 1.5m för µiFidelity® mjukvaruplattform
Regulatory Filings Classification · 1% confidence The document announces a specific business event: Episurf Medical signing a licensing agreement worth SEK 1.5m for its µiFidelity® software platform with an American orthopedic company. This is a material, non-financial announcement regarding a business transaction/partnership. It is not an Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). It does not fit the specific definitions for DIRS, DIV, NAV, or CAP. Since it is a significant business development announcement that doesn't fit the highly specific categories like M&A (TAR) or Share Issue (SHA), it falls best under the general regulatory announcement category, RNS (Regulatory Filings), as it is explicitly stated to be information the company is obliged to make public under EU market abuse regulation.
2020-12-22 Swedish
Episurf Medical enters into licensing agreement of SEK 1.5m for µiFidelity® software platform
M&A Activity Classification · 1% confidence The document announces a specific corporate action: Episurf Medical entering into a licensing agreement worth SEK 1.5m for its µiFidelity® software platform. This is a material event concerning the company's business operations and potential revenue streams, but it does not fit neatly into the defined categories like 10-K, ER, or DIV. It is a specific business transaction announcement. Since it is not a standard regulatory filing like a Director's Dealing (DIRS) or a Major Shareholding (MRQ), and it is not related to capital structure (CAP) or M&A (TAR), the most appropriate general category for a significant, non-standard corporate announcement that is not a report release announcement (RPA) is the general Regulatory Filings fallback category (RNS). The text concludes with a statement about being obliged to make the information public pursuant to the EU Market Abuse Regulation, confirming it is a regulatory disclosure.
2020-12-22 English
Data påvisandes hög implantatsöverlevnad för Episealer® accepterad för publicering
Regulatory Filings Classification · 1% confidence The document is a press release from Episurf Medical announcing that data regarding the survival rate of their Episealer® knee implant has been accepted for publication in a peer-reviewed scientific journal (Surgical Technology International). It details the positive results (>96% survival over 7 years) and includes quotes from the CEO. The final paragraph explicitly states that the information is being made public according to EU market abuse regulation and provides a time/date stamp for disclosure. This is a general regulatory announcement concerning company news/data disclosure, rather than the full report itself (like 10-K or IR), a specific financial filing, or a management change. Since it is an announcement about data/information being made public, and it doesn't fit perfectly into ER, IP, or LTR, the most appropriate general category for regulatory disclosures that don't fit elsewhere is Regulatory Filings (RNS). Given the context of announcing acceptance for publication, RPA could also be considered, but RNS is a broader fit for general regulatory disclosures of this nature.
2020-12-15 Swedish
Data showing high implant survival rate for Episealer® accepted for publication
Regulatory Filings Classification · 1% confidence The document is a short announcement from Episurf Medical stating that post-market surveillance survival data for their Episealer® Knee implant has been accepted for scientific publication in a peer-reviewed journal. It provides key results (>96% survival over 7 years) and quotes the CEO. The text concludes with a statement that this information is made public pursuant to the EU Market Abuse Regulation and was submitted for publication on a specific date. Since the document is short (2757 chars) and its primary function is to announce the *acceptance for publication* of data/a report rather than being the full report itself, it fits best as a general Regulatory Filing or an announcement about a publication. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general regulatory announcement that doesn't fit the specific categories like ER, IR, or LTR, although it is closely related to clinical/product information. However, since it is an announcement about a scientific publication, and not a mandatory financial filing like 10-K or ER, RNS serves as the best general regulatory announcement category.
2020-12-15 English
Episurf Medical carries out a directed share issue and raises proceeds of SEK 66 million
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing that Episurf Medical AB has resolved on a 'directed issue of 36,811,000 shares of series B' to raise proceeds of SEK 66 million. This action directly relates to the company raising capital through the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core event is the resolution to issue shares to raise capital, SHA is the most precise fit, as it covers 'new share issues, stock splits, or other capital changes.' The document details the number of shares, the issue price, the total proceeds, and the resulting dilution, which are key components of a share issue announcement.
2020-11-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.